The rise of Sildenafil initially drove a surge for the drug industry, but recent changes present a uncertain scenario for investors. Generic competitors are eating into earnings, and ongoing legal battles add more risk to the situation. While some companies might still benefit from complementary products, the broader direction suggests a wary appro